Skip to content

Study on the progress of pulmonary nodules based on CT combined with blood metabolic markers

Study on the progress of pulmonary nodules based on CT combined with blood metabolic markers

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074037
Enrollment
Unknown
Registered
2023-07-27
Start date
2022-10-30
Completion date
Unknown
Last updated
2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodule

Interventions

Pulmonary nodule progression group:None
Pulmonary nodule non-progression group:None
Healthy control group:None

Sponsors

Shanghai Tongji Hospital (Tongji Hospital, School of Medicine, Tongji University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 20-80; 2. The chest low-dose CT examination was performed for the first time; 3. There is no obvious cough, weight loss and other abnormal clinical symptoms; 4. Patients with pulmonary nodules must meet the relevant diagnostic criteria in the Chinese Expert Consensus on the Diagnosis and Treatment of Pulmonary Nodules (2018 Edition), that is, chest CT shows that there is at least one focal, quasi circular, solid or sub solid lung shadow with increased density in the lung with a diameter of = 3cm; 5. The clinical data and imaging data are complete. 6. Good compliance and voluntary signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous history of tuberculosis and tumor; 2. Previous treatment of lung nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.); 3. Have a history of pulmonary infection within one month before enrollment; 4. There are metal supports or high-density foreign bodies on the chest and back; 5. Vulnerable groups, such as patients with mental illness, cognitive impairment, critical illness, pregnant women and lactating women; 6. Patients with severe heart, liver and kidney dysfunction.

Design outcomes

Primary

MeasureTime frame
The size of the lung nodule;the blood glucose;the serum lipid;The number of the lung nodule;

Secondary

MeasureTime frame
Serum transaminase;serum bilirubin;Serum alkaline phosphatase;serum ?- Glutamyl transpeptidase;Total serum protein;serum albumin;PT Coagulation time;APTT clotting time;Blood creatinine;Blood urea nitrogen;Blood urea nitrogen;

Countries

China

Contacts

Public ContactYing Xue

Shanghai Tongji Hospital (Tongji Hospital, School of Medicine, Tongji University)

doxy0622@163.com+86 136 7170 0150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026